Rheumatology Unit, Sheba Medical Center, Tel Hashomer, Israel.
Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Ocul Immunol Inflamm. 2022 Oct-Nov;30(7-8):1995-1999. doi: 10.1080/09273948.2021.1922705. Epub 2021 May 20.
To describe the clinical features of patients with bisphosphonate related ocular side effects (BROSE).
The medical records of all patients with BROSE between January 2009 and December 2019 were reviewed.
Nine cases with BROSE were identified. All subjects were female. Median age at diagnosis was of 69 years. The leading indication for bisphosphonate treatment was osteoporosis (n=7), Paget's disease of bone (n=1) and breast cancer (n=1). Six (66.67%) patients presented with uveitis, one (11%) episcleritis and two (22%) with orbital inflammation. Five events (55.5%) occurred within 10 days of initiating the bisphosphonate and the rest (44.44%) developed within 2 weeks to 3 years later. Four (44.44%) patients had concurrent thyroid disease. An association was found between underlying thyroid disease or autoimmunity.
BROSE is an uncommon complication of bisphosphonate therapy occurring more frequently in patients with an autoimmune predisposition.
描述与双膦酸盐相关的眼部副作用（BROSE）患者的临床特征。
回顾了 2009 年 1 月至 2019 年 12 月期间所有 BROSE 患者的病历。
确定了 9 例 BROSE 患者。所有患者均为女性。诊断时的中位年龄为 69 岁。双膦酸盐治疗的主要适应证为骨质疏松症（n=7）、骨 Paget 病（n=1）和乳腺癌（n=1）。6 例（66.67%）患者表现为葡萄膜炎，1 例（11%）为巩膜炎，2 例（22%）为眼眶炎症。5 例（55.5%）事件发生在开始使用双膦酸盐后 10 天内，其余 4 例（44.44%）在 2 周到 3 年后发生。4 例（44.44%）患者同时患有甲状腺疾病。发现潜在的甲状腺疾病或自身免疫与 BROSE 之间存在关联。
BROSE 是双膦酸盐治疗的一种罕见并发症，在自身免疫倾向的患者中更为常见。
